{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:59:45Z","timestamp":1781243985821,"version":"3.54.1"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oral Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Medication-related osteonecrosis of the jaw (MRONJ) is a serious complication associated with bone-modifying agents, including denosumab. The clinical course after denosumab discontinuation remains insufficiently understood, and optimal surgical strategies for advanced cases are still under debate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report a 71-year-old man with castration-resistant prostate cancer and multiple bone metastases who developed MRONJ during denosumab therapy for more than 3 years. After diagnosis at our institution, denosumab was discontinued based on the decision of the treating oncologist. Rapid progression of bone resorption was observed within several months, in which discontinuation of denosumab may have been a contributing factor. Although segmental mandibulectomy was considered, the patient declined radical surgery. Marginal mandibulectomy was therefore performed via an intraoral approach, with preservation of the lingual bone plate and periosteum. During long-term follow-up, marked bone regeneration became evident by 2 years postoperatively and was sustained at 6 years, with restoration of mandibular continuity. No recurrence of MRONJ or new skeletal-related events was observed during ongoing oncological follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Discontinuation of denosumab may have contributed to rapid osteolytic progression in MRONJ. Preservation of biological structures during marginal mandibulectomy, as part of multidisciplinary management, may be associated with favorable bone regeneration. These findings highlight the complexity of MRONJ management and the importance of individualized, multidisciplinary approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/froh.2026.1848520","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:44:54Z","timestamp":1781243094000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Mandibular bone regeneration after marginal mandibulectomy for advanced MRONJ following denosumab discontinuation: a case report"],"prefix":"10.3389","volume":"7","author":[{"given":"Wataru","family":"Kotani","sequence":"first","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine","place":["Mibu, Tochigi, Japan"]},{"name":"Ichigaya Concier Dental Clinic","place":["Chiyoda-ku, Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonji","family":"Fukumoto","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine","place":["Mibu, Tochigi, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Hyodo","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine","place":["Mibu, Tochigi, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuske","family":"Komiyama","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine","place":["Mibu, Tochigi, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine","place":["Mibu, Tochigi, Japan"]},{"name":"Section of Dentistry, Oral and Maxillofacial Surgery, Sano Kosei General Hospital , Sano","place":["Tochigi, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Wakui","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine","place":["Mibu, Tochigi, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kawamata","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine","place":["Mibu, Tochigi, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J Oral Maxillofac Surg"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-related osteonecrosis of the jaw: mASCC\/ISOO\/ASCO clinical practice guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1007\/s00520-022-06839-4","article-title":"Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study","volume":"30","author":"Hata","year":"2022","journal-title":"Support Care Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s00520-018-4501-x","article-title":"Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review","volume":"27","author":"Nicolatou-Galitis","year":"2019","journal-title":"Support Care Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1111\/odi.13160","article-title":"Workshop of European task force on medication-related osteonecrosis of the jaw\u2014current challenges","volume":"77","author":"Schiodt","year":"2019","journal-title":"J Oral Maxillofac Surg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of bone-modifying agents in metastatic breast cancer: an American society of clinical oncology-cancer care ontario focused guideline update","volume":"35","author":"Van Poznak","year":"2017","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1007\/s00520-017-3826-9","article-title":"Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese allied committee on osteonecrosis of the jaw","volume":"25","author":"Yoneda","year":"2017","journal-title":"Support Care Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.joms.2009.01.006","article-title":"The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws","volume":"67","author":"Carlson","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab therapy","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"B12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jcms.2009.10.005","article-title":"Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on bone cells","volume":"38","author":"Otto","year":"2010","journal-title":"J Craniomaxillofac Surg"},{"key":"B14","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1359\/jbmr.081003","article-title":"Skeletal cell fate decisions within periosteum and bone marrow during bone regeneration","volume":"44","author":"Colnot","year":"2009","journal-title":"Bone Miner Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1089\/ten.TEB.2014.0591","article-title":"Uncovering the periosteum for skeletal regeneration: the stem cell that lies beneath","volume":"21","author":"Roberts","year":"2015","journal-title":"Tissue Eng Part B Rev"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1111\/odi.14887","article-title":"Italian Position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ)","volume":"30","author":"Bedogni","year":"2024","journal-title":"Oral Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1634\/theoncologist.2012-0331","article-title":"Efficacy and safety of bone-modifying agents in metastatic cancer: clinical considerations and duration of therapy","volume":"18","author":"Amadori","year":"2013","journal-title":"Oncologist"},{"key":"B18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jclinepi.2013.08.003","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"67","author":"Gagnier","year":"2014","journal-title":"J Clin Epidemiol"}],"container-title":["Frontiers in Oral Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/froh.2026.1848520\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:44:55Z","timestamp":1781243095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/froh.2026.1848520\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":18,"alternative-id":["10.3389\/froh.2026.1848520"],"URL":"https:\/\/doi.org\/10.3389\/froh.2026.1848520","relation":{},"ISSN":["2673-4842"],"issn-type":[{"value":"2673-4842","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"article-number":"1848520"}}